RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Solute carrier transporters in tumor metabolism and tumor immunity.
Solute carrier transporters in tumor metabolism and tumor immunity.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
溶质载体转运蛋白(SLCs)的研究已成为一个成熟的领域,揭示了这些蛋白质在肿瘤生物学中的功能作用。SLC转运蛋白是跨膜蛋白,通常包含7至12个跨膜结构域,介导多种基本功能,包括代谢物(如葡萄糖、氨基酸和脂质)的转运、信号转导、免疫细胞相互作用以及线粒体稳态的调节。SLC转运蛋白的表达具有组织、疾病和时空特异性,越来越多的证据表明SLC转运蛋白与病理状态,特别是肿瘤预后密切相关。鉴于其系统发育或物种保守性、肿瘤组织特异性表达以及靶向特定通路的潜力,SLC转运蛋白有望成为肿瘤诊断、治疗和预后的生物标志物。SLC转运蛋白在肿瘤代谢和肿瘤免疫中发挥重要作用,不仅影响肿瘤细胞,还影响肿瘤微环境中的免疫成分,如T细胞、NK 细胞和巨噬细胞。在这篇综述中,我们全面审视了SLC在肿瘤代谢免疫和肿瘤免疫中的功能,重点阐述了它们对肿瘤细胞代谢重编程和肿瘤微环境中免疫细胞功能的影响。
我们还概述了SLC结构、SLC药理学以及靶向SLC的抗癌治疗的最新进展,特别是那些具有临床疗效的治疗。最后,我们讨论了SLC转运蛋白领域当前面临的挑战,并提出了未来的研究方向。
Research on solute carrier transporters (SLCs) has become a well-established field, revealing the functional roles of these proteins in cancer biology. SLC transporters are transmembrane proteins that typically contain 7 to 12 transmembrane domains and mediate numerous essential functions, including transport of metabolites (such as glucose, amino acids, and lipids), signal transduction, immune cell interaction, and regulation of mitochondrial homeostasis. The expression of SLC transporters shows tissue, disease, and spatiotemporal specificity, and accumulating evidence indicates that SLC transporters are closely associated with pathological conditions, particularly tumor prognosis.
Given their phylogenetic or species conservation, tumor tissue-specific expression, and potential to target specific pathways, SLC transporters hold promise as biomarkers for tumor diagnosis, treatment, and prognosis. SLC transporters play significant roles in tumor metabolism and tumor immunity, affecting not only tumor cells but also immune components of the tumor microenvironment, such as T cells, natural killer cells, and macrophages.
In this review, we thoroughly examine the functions of SLCs in tumor metabolism immunity and tumor immunity, highlighting their impact on metabolic reprogramming of tumor cells and immune cell function within the tumor microenvironment.
We also provide an overview of the SLC structure, SLC pharmacology, and recent advances in anticancer therapies targeting SLCs, particularly those with clinical efficacy.
Finally, we discuss current challenges in the field of SLC transporters and propose future research directions.
MEMBER ACCOUNT
登录成功会直接打开下一页。